Copenhagen-based Neumirna Therapeutics has raised €20M in a Series A funding round, co-led by Angelini Ventures and Invivo Partners, with continued support from Innovestor’s Life Science Fund and other investors. Founded in 2020, Neumirna is pioneering RNA-based therapies, focusing on microRNA-targeted solutions for neurological disorders like drug-resistant epilepsy (DRE) and Parkinson’s disease. The funding will accelerate clinical trials for its lead candidate, NMT.001, an Antisense Oligonucleotide therapy showing promising preclinical results for DRE. The investment will also bolster R&D efforts and scale Neumirna’s platform, furthering its mission to deliver transformative treatments.
Neumirna was founded with the mission to revolutionize the treatment paradigms for challenging neurological conditions, and is at the forefront of RNA therapeutics, harnessing the power of microRNAs (miRNAs) to provide disease-modifying drugs. The company’s pioneering drug discovery platform enables the development of RNA therapies targeting previously intractable conditions, such as drug-resistant epilepsy (DRE) and Parkinson’s disease (PD).
“This funding milestone is a testament to the groundbreaking potential of our RNA-based platform and our lead development candidate, NMT.001” said Professor Janine Erler, CEO of Neumirna Therapeutics. “We are thrilled to have the support of leading international investors, who share our vision of addressing the unmet needs of patients living with neurological disorders. This funding is essential to bring NMT.001 to clinical trials and advance our pipeline.”
Neumirna’s lead therapeutic candidate, NMT.001, is an Antisense Oligonucleotide (ASO) therapy addressing DRE, a condition affecting millions of patients worldwide who remain underserved by current treatment options. Preclinical studies show unprecedented efficacy in animal models of DRE, highlighting the potential of NMT.001 to significantly improve patient outcomes and quality of life.
With the new funding, Neumirna is poised to expand its research and development, scale its platform, and drive NMT.001 through the next key stages of development. This funding round marks a pivotal moment for Neumirna as it advances toward its goal of delivering life-changing therapies to patients in need.
“As co-lead investors, we are proud to support Neumirna in its mission to harness the potential of RNA therapies to tackle epilepsy and other complex neurological disorders,” said Thomas Thestrup, Senior Principal at Angelini Ventures. “By leveraging microRNA-targeted drugs to address the underlying causes of diseases like epilepsy and Parkinson’s disease, Neumirna is breaking new ground in the field. With our strong focus on brain disorders and a commitment to advancing innovative treatments for epilepsy, we are excited to collaborate with Neumirna’s management team on this journey to develop transformative solutions for patients worldwide.”
“Investing in Neumirna represents a unique opportunity to support a pioneering company in leveraging RNA technology to treat neurological diseases,” said Luis Pareras, Managing Partner at Invivo Partners. “As a neurosurgeon, I am deeply impressed by the innovative approach and the results of NMT.001. The possibility of offering a transformative solution for patients with refractory, drug-resistant epilepsy, a devastating condition, is tremendously encouraging.”
Both Luis Pareras and Thomas Thestrup have been appointed to the Board of Directors, joining Milla Koistinaho, from Innovestor’s Life Science Fund, and Dr. Henrik Klitgaard, Scientific co-Founder of Neumirna Therapeutics.
Click to read more funding news.
Read the orginal article: https://arcticstartup.com/neumirna-therapeutics-raises-e20m-in-series-a/
